These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28717233)

  • 1. Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia.
    Climent E; Pérez-Calahorra S; Marco-Benedí V; Plana N; Sánchez R; Ros E; Ascaso JF; Puzo J; Almagro F; Lahoz C; Civeira F; Pedro-Botet J
    Sci Rep; 2017 Jul; 7(1):5596. PubMed ID: 28717233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes.
    Climent E; Pérez-Calahorra S; Benaiges D; Pintó X; Suárez-Tembra M; Plana N; Sánchez-Hernández RM; Valdivielso P; Ascaso JF; Pedro-Botet J
    Rev Esp Cardiol (Engl Ed); 2020 Sep; 73(9):718-724. PubMed ID: 31672559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
    Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
    Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
    Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
    Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia.
    Cao YX; Zhou BY; Sun D; Li S; Guo YL; Zhu CG; Wu NQ; Gao Y; Xu RX; Liu G; Dong Q; Li JJ
    Per Med; 2019 Nov; 16(6):467-478. PubMed ID: 31691639
    [No Abstract]   [Full Text] [Related]  

  • 6. Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle.
    Shek A; Alieva R; Kurbanov R; Hoshimov S; Nizamov U; Abdullaeva G; Nagay A
    Atherosclerosis; 2018 Oct; 277():524-529. PubMed ID: 30270094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
    Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
    Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
    Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
    J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins.
    Rallidis LS; Triantafyllis AS; Tsirebolos G; Katsaras D; Rallidi M; Moutsatsou P; Lekakis J
    Atherosclerosis; 2016 Jun; 249():17-21. PubMed ID: 27062405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients.
    Pérez-Calahorra S; Sánchez-Hernández RM; Plana N; Marco-Benedi V; Pedro-Botet J; Almagro F; Brea A; Ascaso JF; Lahoz C; Civeira F;
    Am J Cardiol; 2017 Mar; 119(5):742-748. PubMed ID: 28081939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry.
    Roy G; Couture P; Genest J; Ruel I; Baass A; Bergeron J; Brisson D; Brunham LR; Cermakova L; Gaudet D; Khoury E; Laflamme N; Kennedy BA; Hegele RA; Drouin-Chartier JP
    Can J Cardiol; 2022 Mar; 38(3):311-319. PubMed ID: 34774719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aortic Calcification Progression in Heterozygote Familial Hypercholesterolemia.
    Al Kindi M; Bélanger AM; Sayegh K; Senouci S; Aljenedil S; Sivakumaran L; Ruel I; Al Rasadi K; Al Waili K; Awan Z; Valenti D; Genest J
    Can J Cardiol; 2017 May; 33(5):658-665. PubMed ID: 28449836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype.
    Drouin-Chartier JP; Tremblay AJ; Hogue JC; Ooi TC; Lamarche B; Couture P
    Metabolism; 2015 Nov; 64(11):1541-7. PubMed ID: 26371983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioural cardiovascular risk factors and prevalence of diabetes in subjects with familial hypercholesterolaemia.
    Perez-Calahorra S; Civeira F; Guallar-Castillón P; Pinto X; Banegas JR; Pedro-Botet J; Suarez-Tembra M; Mauri M; Soler C; Rodriguez-Artalejo F; Laclaustra M
    Eur J Prev Cardiol; 2020 Oct; 27(15):1649-1660. PubMed ID: 31914797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus.
    Besseling J; Kastelein JJ; Defesche JC; Hutten BA; Hovingh GK
    JAMA; 2015 Mar; 313(10):1029-36. PubMed ID: 25756439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
    Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M
    J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The detection of heterozygous familial hypercholesterolemia in Ireland.
    O'Kane MJ; Menown IB; Graham I; Maher V; Tomkin G; Nicholls P; Graham C
    Adv Ther; 2012 May; 29(5):456-63. PubMed ID: 22610724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.